Novartis is buying Avidity Biosciences for $12 billion, picking up RNA-based medicines for neuromuscular diseases as it seeks ...
Since interagency cooperation isn’t succeeding organically, it’s time for top-down initiatives led by a Health and Human ...
Sometimes the biggest moments at a conference happen backstage. At the annual STAT Summit, that kind of moment involved a ...
Researchers worry that Medicaid home care eligibility decisions are often made without public scrutiny and based less on ...
Advocacy groups form a buyer’s club to obtain generic versions of pricey Vertex cystic fibrosis drug
Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...
The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in ...
Submit a response to a recent First Opinion essay below. Selected submissions will appear in our weekly letter to the editor roundup, published every Saturday.
Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.
TrumpRx and a most-favored nation policy won’t lower prices for patients, writes the CEO and co-founder of I-MAK.
The Food and Drug Administration yesterday delivered a split decision on GSK’s blood cancer drug Blenrep, approving its use ...
More than 420 anti-science bills attacking longstanding public health protections have been introduced in statehouses across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback